Condition
Friedreich Ataxia clinical trials and research
As of November 12, 2026, Find a Trial lists 13 Friedreich Ataxia clinical trials that are recruiting, at sites in 17 countries (most in United States (9), France (5), Germany (4)). By phase: Phase 2 (2), Phase 1/2 (1), Phase 1 (1), Phase 3 (1). The most active sponsors are Biogen (2), Centre Hospitalier Universitaire de Nice (2), Lexeo Therapeutics (2). There are also 3 NIH-funded research projects on Friedreich Ataxia, with $1.7 million in listed awards. Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 13Clinical trials
- 3NIH research projects
- 17Countries
Newest Friedreich Ataxia clinical trials
All recruiting trials (13)
-
Nomlabofusp by injection for Friedreich's Ataxia: efficacy and safety
This study tests whether subcutaneous nomlabofusp helps adults and children with Friedreich's Ataxia compared with placebo.
-
LX2006 Gene Therapy for Friedreich Ataxia Cardiomyopathy (FA-CM)
A Phase 2 study tests LX2006 gene therapy in people with Friedreich ataxia who also have cardiomyopathy to see if it helps heart function and safety.
-
Nerve ultrasound in people with Friedreich ataxia
This project uses routine peripheral nerve ultrasound to see if adults with genetically confirmed Friedreich ataxia have enlarged nerves.
-
Omaveloxolone for swallowing problems in French people with Friedreich's ataxia
This project will test whether omaveloxolone (SKYCLARYS) improves swallowing in French people aged 16 and older with genetically confirmed Friedreich's ataxia who have used the drug for at least six months.
-
Testing DT-216P2 in patients with Friedreich's Ataxia
This study is testing a new drug called DT-216P2 in adults with Friedreich's Ataxia to see how safe it is and how well it works in their bodies.
-
Clinical course of cardiomyopathy in people with Friedreich ataxia
This study follows people with Friedreich ataxia who have cardiomyopathy to see how their heart disease changes over time and to identify who may later be eligible for a gene therapy study.
-
Health effects of omaveloxolone taken during pregnancy or breastfeeding in people with Friedreich's Ataxia
See if taking BIIB141 (omaveloxolone) during pregnancy or while breastfeeding affects the health of people with Friedreich's Ataxia and their babies.
-
Long-term safety assessment of omaveloxolone in Friedreich's Ataxia patients
This study is testing the long-term safety of the drug omaveloxolone in people with Friedreich's Ataxia to see if it causes any serious side effects like liver problems or heart issues.
-
Long-term CTI-1601 (nomlabofusp) treatment for Friedreich's ataxia
This trial tests daily subcutaneous CTI-1601 (nomlabofusp) in children (age 2+), adolescents, and adults with Friedreich's ataxia to see long-term safety, drug levels, biological effects, and clinical response.
-
Global study on the natural history of Friedreich Ataxia
This study looks at how Friedreich Ataxia changes over time in people with the condition to better understand its progression and improve future treatments.
-
Assessing health and economic outcomes in Friedreich Ataxia patients
This study is trying to understand how Friedreich Ataxia affects the lives and finances of patients by using a mobile app to gather information over six months.
-
Gene therapy for heart issues in Friedreich's ataxia
This study is testing a new gene therapy for heart problems in people with Friedreich's ataxia to see if it is safe and helps improve their heart function.
-
Registry for patients with rare diseases
This study is creating a central registry for people with rare diseases to help connect them with researchers and improve treatments.
NIH-funded research (3)
Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.
-
Understanding early Friedreich ataxia in children to improve how we measure outcomes
This study looks at how Friedreich ataxia starts and progresses in kids to create better, child-friendly measures for tracking the disease and testing treatments.
-
Blocking the p38 stress protein to help people with Friedreich ataxia
Looks at whether blocking the p38 stress-response protein can improve cell health and reduce nerve and heart damage in people with Friedreich ataxia.
-
Targeting p38 MAPK to treat Friedreich ataxia
This study is looking at how a specific pathway in the body might be making Friedreich ataxia worse, and it hopes to find new treatments that could help improve symptoms and slow down the disease for those living with it.
Related topics
Quick answers
How many Friedreich Ataxia clinical trials are recruiting right now?
13, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 17 countries. The most sites are in United States (9 trials), France (5 trials), Germany (4 trials), Austria (3 trials), Czechia (3 trials). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 2, Phase 1/2: 1, Phase 1: 1, Phase 3: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.